An update on Merkel cell carcinoma
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2023-05 · 1878 (3) · 188880
DOI: 10.1016/j.bbcan.2023.188880 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023-05. Verfasst von Maria Chiara Sergi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Skin Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 103 Literaturangaben. Gefördert von: Associazione Italiana per la Ricerca sul Cancro.
Abstract (Originalsprache)
Merkel cell carcinoma (MCC) is a rare cancer of the skin characterized by a neuroendocrine phenotype and an aggressive clinical behavior. It frequently originates in sun-exposed body areas, and its incidence has steadily increased in the last three decades. Merkel cell polyomavirus (MCPyV) and ultraviolet (UV) radiation exposure are the main causative agents of MCC, and distinct molecular features have been documented in virus-positive and virus-negative malignancies. Surgery remains the cornerstone of treatment for localized tumors, but even when integrated with adjuvant radiotherapy is able to definitively cure only a fraction of MCC patients. While characterized by a high objective response rate, chemotherapy is associated with a short-lasting benefit of approximately 3 months. On the other hand, immune checkpoint inhibitors including avelumab and pembrolizumab have demonstrated durable antitumor activity in patients with stage IV MCC, and investigations on their use in the neoadjuvant or adjuvant setting are currently underway. Addressing the needs of those patients who do not persistently benefit from immunotherapy is currently one of the most compelling unmet needs in the field, and multiple clinical trials of new tyrosine kinase inhibitors (TKIs), peptide receptor radionuclide therapy (PRRT), therapeutic vaccines, immunocytokines as well as innovative forms of adoptive cellular immunotherapies are under clinical scrutiny at present.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy.
- Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy; Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy.
- Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy; Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy. Electronic address: mauro.cives@uniba.it.
Förderung
- Associazione Italiana per la Ricerca sul Cancro
Zitieren
APA
Sergi, M. C., Lauricella, E., Porta, C., Tucci, M., & Cives, M. (2023). An update on Merkel cell carcinoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1878(3), 188880. https://doi.org/10.1016/j.bbcan.2023.188880
Vancouver
Sergi MC, Lauricella E, Porta C, Tucci M, Cives M. An update on Merkel cell carcinoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2023;1878(3):188880. doi:10.1016/j.bbcan.2023.188880
BibTeX
@article{Sergi2023,
author = {Sergi, Maria Chiara and Lauricella, Eleonora and Porta, Camillo and Tucci, Marco and Cives, Mauro},
title = {An update on Merkel cell carcinoma},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2023},
volume = {1878},
number = {3},
pages = {188880},
doi = {10.1016/j.bbcan.2023.188880}
}
EUVIMED